Baseline Lymphopenia: A Predictor Of Poor Outcomes In HER2 positive Metastatic Breast Cancer Treated With Trastuzumab.

Yi-Qun CheYue ZhangDi WangHui-Ying LiuDi Shen Yang Luo

Published in: Drug design, development and therapy (2019)

Our data indicate that baseline ALC value of ≤1 G/L is a predictor of poor outcomes, but not of response, in patients with MBC treated with trastuzumab.

Keyphrases

metastatic breast cancer
epidermal growth factor receptor
electronic health record
type diabetes
big data
newly diagnosed
machine learning
insulin resistance
adipose tissue
metabolic syndrome
glycemic control
deep learning
tyrosine kinase